The average share price for stem cell companies a paltry $1.62 per share, although 2/3 of the companies fall below this, and I know that the median would be a better indicator of share price than is the average, but the $1.62 average is all that Seeking Alpha gave, so I am going with it.
So with ACTC at $0.071 per share, it's currently 228% below the average of other stem cell companies. This along with ACT being further along in it's ESC trials than any other company, makes me ask why? And it's clear to me that the cause of this dismal share price performance, is the CEO, now at the helm of ACT.
So who do you blame? And Theres, please don't respond, because I know that you'll blindly defend Gary to the very end. Besides you lost tons of cred, when you voted twice for GW.
Keep, you started this whole thread with this statement. "So with ACTC at $0.071 per share, it's currently 228% below the average of other stem cell companies." I simply pointed out that its a meaningless comparison and you've done nothing to defend your own statement. You just run from it. So who's the blockhead?
I'll respond anytime that I please. You once again demonstrate your total ignorance. The price of a stock is meaningless. It's market cap that matters and ACT is at the high end. How else can you explain an 80:1 RS having no impact on the value of the company. Try a passbook savings account on for size. More your speed.
"The price of a stock is meaningless. It's market cap that matters and ACT"
Theres, I won't call you ignorant making this statement, like you've called me many times before, but I will say you haven't a clue how the market cap is calculated. Once again:
SHARE PRICE X SHARES OUTSTANDING = MARKET CAP
Now if the share price is meaningless then cap would just be the amount outstanding shares, which right now would make the cap = $2.3B
TNBH....please clarify:How else can you explain an 80:1 RS having no impact on the value of the company. Clearly the issue of the R/S has impacted investor confidence/SP whether as a holder or prospective buyer. How do I know this? Rabin said so.